Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 11 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Microbot Medical Inc. | 273,759 | reported | 01 Jan 2016 | tx 13+341,759 |
| CERUS CORP | 222,133 | reported | 03 Jun 2025 | tx 24+425,131−41,791 |
| SUNESIS PHARMACEUTICALS INC | 95,000 | reported | 30 Nov 2016 | tx 44+2,880,781−120,430 |
| Mirum Pharmaceuticals, Inc. | 49,788 | reported | 16 Mar 2026 | tx 33+381,468−88,962 |
| GRAYBUG VISION, INC. | 10,000 | reported | 27 Aug 2024 | tx 18+121,184−1,429 |
| Metagenomi Therapeutics, Inc. | 8,572 | reported | 10 Jun 2025 | tx 2+50,572 |
| Surrozen, Inc./DE | 5,550 | reported | 13 May 2026 | tx 4+28,216 |
| ADURO BIOTECH, INC. | 0 | reported | 11 Aug 2023 | tx 33+482,865−501,769 |
| Corium International, Inc. | 0 | reported | 27 Nov 2018 | tx 14+86,500−86,500 |
| Aimmune Therapeutics, Inc. | 0 | reported | 13 Oct 2020 | tx 25+514,020−516,615 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 13 May 2026 | GRANT_AWARD | Surrozen, Inc./DE | 5,550 | 0.00 USD | deriv |
| 16 Mar 2026 | SALE | Mirum Pharmaceuticals, Inc. | 7,287 | 91.98 USD | |
| 15 Mar 2026 | EXERCISE | Mirum Pharmaceuticals, Inc. | 13,334 | — | |
| 15 Mar 2026 | EXERCISE | Mirum Pharmaceuticals, Inc. | 13,334 | 0.00 USD | deriv |
| 28 Jan 2026 | GRANT_AWARD | Mirum Pharmaceuticals, Inc. | 18,140 | 0.00 USD | deriv |
| 28 Jan 2026 | GRANT_AWARD | Mirum Pharmaceuticals, Inc. | 11,760 | 0.00 USD | deriv |
| 28 Jan 2026 | GRANT_AWARD | Mirum Pharmaceuticals, Inc. | 20,000 | 0.00 USD | deriv |
| 23 Jan 2026 | EXERCISE | Mirum Pharmaceuticals, Inc. | 2,667 | — | |
| 26 Jan 2026 | SALE | Mirum Pharmaceuticals, Inc. | 1,053 | 96.19 USD | |
| 23 Jan 2026 | EXERCISE | Mirum Pharmaceuticals, Inc. | 2,667 | 0.00 USD | deriv |
| 22 Jan 2026 | SALE | Mirum Pharmaceuticals, Inc. | 1,421 | 93.33 USD | |
| 21 Jan 2026 | EXERCISE | Mirum Pharmaceuticals, Inc. | 3,334 | — | |
| 21 Jan 2026 | EXERCISE | Mirum Pharmaceuticals, Inc. | 3,334 | 0.00 USD | deriv |
| 11 Sept 2025 | EXERCISE | Mirum Pharmaceuticals, Inc. | 18,333 | — | |
| 12 Sept 2025 | SALE | Mirum Pharmaceuticals, Inc. | 9,578 | 76.01 USD | |
| 11 Sept 2025 | EXERCISE | Mirum Pharmaceuticals, Inc. | 18,333 | 0.00 USD | deriv |
| 12 Aug 2025 | EXERCISE | Mirum Pharmaceuticals, Inc. | 2,954 | 26.49 USD | |
| 11 Aug 2025 | SALE | Mirum Pharmaceuticals, Inc. | 8,000 | — | |
| 12 Aug 2025 | EXERCISE | Mirum Pharmaceuticals, Inc. | 2,954 | 0.00 USD | deriv |
| 10 Jun 2025 | GRANT_AWARD | Metagenomi Therapeutics, Inc. | 8,572 | 0.00 USD | deriv |
| 03 Jun 2025 | GRANT_AWARD | CERUS CORP | 60,000 | 0.00 USD | |
| 14 May 2025 | GRANT_AWARD | Surrozen, Inc./DE | 1,333 | 0.00 USD | deriv |
| 03 Feb 2025 | GRANT_AWARD | Metagenomi Therapeutics, Inc. | 42,000 | 0.00 USD | deriv |
| 23 Jan 2025 | EXERCISE | Mirum Pharmaceuticals, Inc. | 2,667 | — | |
| 23 Jan 2025 | EXERCISE | Mirum Pharmaceuticals, Inc. | 2,667 | 0.00 USD | deriv |
4 purchases reported after at least 12 months of silence — most recent on 16 May 2023.